Long-term study of zasocitinib for psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study is for people with psoriatic arthritis who have already completed a year-long treatment with zasocitinib or a similar medicine in a previous study. It tests whether continuing to take zasocitinib remains safe and helpful over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have completed the full 52-week treatment period in a prior related study (TAK-279-PsA-3001 or TAK-279-PsA-3002).
- You did not have to stop taking the study drug early in the previous study.
- Your doctor believes you may benefit from continuing or starting zasocitinib.
- You are 18 years or older (19 or older in South Korea).
- You have not developed new conditions like rheumatoid arthritis, lupus, or other diseases that might affect study results since the previous study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This study tests an investigational medication (zasocitinib) taken by mouth to reduce joint pain, swelling, and skin symptoms in adults with psoriatic arthritis. It is for people whose symptoms have not improved enough with standard treatments.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
This study is for people who have already been in a previous trial of sonelokimab for psoriatic arthritis and want to continue treatment. It checks how safe and effective the medicine is over a longer time.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.